KRYSTAL BIOTECH, INC.
KRYSLoading price...
Overview
Previous Close341.12
Open320.70
Ask342.46
Bid313.27
Day's Range297.02 - 332.30
52 Week Range130.50 - 382.54
PE Ratio(TTM)41.84
Market Cap9.21B
Volume1.17M
Avg. Volume427.48k
12 Months Earnings225.03M
12 Months Revenue417.30M
Performance
ABSCAGR
| YTD | 1 Month | 3 Months | 1 Year | 2 Years | 5 Years | 10 Years | |
|---|---|---|---|---|---|---|---|
| No results to display | |||||||
Profit/Loss
| PARTICULARS | TTM | 2025 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Operating Revenue | 417.30M | 389.13M | 359.20M | 290.51M | 50.70M | 0.00 |
| Cost of Revenue | 24.34M | 23.05M | 23.83M | 20.06M | 3.09M | 0.00 |
| Gross Profit | 392.96M | 366.08M | 335.38M | 270.45M | 47.60M | 0.00 |
| Operating Expenses | 214.23M | 204.79M | 183.58M | 167.21M | 144.72M | 120.20M |
| Profit after Tax (Net Income) | 225.03M | 204.83M | 146.72M | 89.16M | 10.93M | -139.97M |
Company Profile
Sector: Healthcare
Industry: Biotechnology
HQ Location: Pittsburgh, United States
Website: https://www.krystalbio.com
Founder, Chairman, President & CEO: Mr. Krish S. Krishnan M.B.A., M.S.
Employees: 295
About Company:
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.